- Insulet Corporation's Omnipod 5 App for iPhone now supports Dexcom G7, enhancing diabetes management for U.S. users.
- The integration allows users to manage insulin delivery and track glucose levels conveniently from their iPhone.
- The app is available for download on the Apple App Store, reflecting Insulet's commitment to advancing diabetes technology.
Insulet Corporation (PODD, Financial), a leader in tubeless insulin pump technology, has announced the integration of Dexcom G7 Continuous Glucose Monitoring (CGM) System with its Omnipod 5 App for iPhone. This development enables U.S. users to manage their diabetes more conveniently through their smartphones.
The integration combines the Omnipod 5 Automated Insulin Delivery System's benefits with Dexcom's latest diabetes management technology. The app allows users to control insulin delivery, adjust settings, and access valuable insights seamlessly from an iPhone. This innovation simplifies diabetes management by reducing the number of devices required.
"This integration marks a significant milestone in our effort to offer innovative solutions for diabetes management," said Eric Benjamin, Insulet's Executive Vice President and Chief Product and Customer Experience Officer. Users can now download the Omnipod 5 App with Dexcom G7 and Dexcom G6 compatibility from the Apple App Store.
Insulet Corporation (PODD, Financial) continues its dedication to improving diabetes management technology and enhancing the quality of life for those with diabetes, further cementing its position in the medical devices sector.
